Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (256)	7/28/2004 6:10:36 PM
From: Biomaven	Read Replies (2) \| Respond to of 946

Hey - maybe they are boosting the morale of patients involved in the trial by offering them rides on the jet. <g> Nice bounce after the offering. That's historically been a good indicator in biotech. Peter

To: Icebrg who wrote (256)	7/29/2004 3:34:17 AM
From: Icebrg	Respond to of 946

Cell Therapeutics Adds To Cash With $42.8M Offering There is some commentary from BioWorld available at bioworld.com There are some comments from Bianco on the efforts leading to the successful (?) share issue. He further is mentioning with regard to Stellar 3 that "We just passed the 200-death point in late June, so we won't get to 311 events until late December, and the data won't be available until January." If they reached 200 events at the end of June the medium survival event should have happened sometimes towards the middle of June, I guess, as the total number of enrollees was 370. Erik